Evidence map›Paper›PMID 37414216›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2023

Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.

S H Cass, J W D Tobin, Y D Seo, G Gener-Ricos, E Z Keung, E M Burton, M A Davies, J L McQuade, A J Lazar, R Mason and 23 more

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Clinical and histopathological features of advanced cutaneous squamous cell carcinoma with varying responses to cemiplimab.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 11 institutions in 3 countries.

S H CassDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.
J W D TobinHaematology Department, Princess Alexandra Hospital, Woolloongabba; University of Queensland, Brisbane, Australia.
Y D SeoDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.
G Gener-RicosDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston.
E Z KeungDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.
E M BurtonDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
M A DaviesDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
J L McQuadeDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
A J LazarDepartments of Pathology and Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, USA.
R MasonGold Coast University Hospital, Southport.
M MillwardUniversity of Western Australia, Perth.
S SandhuPeter Macallum Cancer Centre, Melbourne.
C KhooPeter Macallum Cancer Centre, Melbourne.
L WarburtonFiona Stanley Hospital, Perth; Edith Cowan University, Joondalup; Future Health Research and Innovation Fund/Raine Clinician Research Fellowship.
V GuerraDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston.
A HaydonAlfred Hospital, Melbourne.
H DeardenMelanoma Institute Australia, The University of Sydney, Sydney.
A M MenziesMelanoma Institute Australia, The University of Sydney, Sydney; Faculty of Medicine and Health, The University of Sydney, Sydney; The University of Sydney Charles Perkins Centre, Sydney; The University of Sydney Royal North Shore and Mater Hospitals, Sydney.
M S CarlinoMelanoma Institute Australia, The University of Sydney, Sydney; Westmead Hospital, Sydney, Australia.
J L SmithWestmead Hospital, Sydney, Australia.
P MolleeHaematology Department, Princess Alexandra Hospital, Woolloongabba; University of Queensland, Brisbane, Australia.
M BurgessHaematology Department, Princess Alexandra Hospital, Woolloongabba; University of Queensland, Brisbane, Australia.
S MappHaematology Department, Princess Alexandra Hospital, Woolloongabba; University of Queensland, Brisbane, Australia.
C KeaneHaematology Department, Princess Alexandra Hospital, Woolloongabba; University of Queensland, Brisbane, Australia.
V AtkinsonHaematology Department, Princess Alexandra Hospital, Woolloongabba; University of Queensland, Brisbane, Australia.
S A ParikhMayo Clinic, Rochester, USA.
S N MarkovicMayo Clinic, Rochester, USA.
W DingMayo Clinic, Rochester, USA.
T G CallMayo Clinic, Rochester, USA.
P J HampelMayo Clinic, Rochester, USA.
G V LongMelanoma Institute Australia, The University of Sydney, Sydney; Faculty of Medicine and Health, The University of Sydney, Sydney; The University of Sydney Charles Perkins Centre, Sydney; The University of Sydney Royal North Shore and Mater Hospitals, Sydney.
J A WargoDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: jwargo@mdanderson.org.
A FerrajoliDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston.
The University of Texas MD Anderson Cancer Center · USThe University of Queensland · AUMayo Clinic in Florida · USPeter MacCallum Cancer Centre · AUThe University of Sydney · AUWestmead Hospital · AUEdith Cowan University · AUGold Coast Hospital · AUMater Hospital · GBThe Alfred Hospital · AUThe University of Western Australia · AU

Funding

The University of Texas MD Anderson Cancer Center SPORE in MelanomaP50CA221703 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAVIES, MICHAEL · 2019 to 2023
$10.3M
Transdisciplinary Research in Energetics and Cancer (TREC) Training GrantR25CA203650 · NCI · YALE UNIVERSITY · PI IRWIN, MELINDA L · 2016 to 2025
$2.9M
(PQ10) Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiomeR01CA219896 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WARGO, JENNIFER A. · 2018 to 2022
$2.2M
NCI NIH HHS P50 CA221703NCI NIH HHS R01 CA219896NCI NIH HHS R25 CA203650
6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICIs) have revolutionized the management of advanced melanoma (AM). However, data on ICI effectiveness have largely been restricted to clinical trials, thereby excluding patients with co-existing malignancies. Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia and is associated with increased risk of melanoma. CLL alters systemic immunity and can induce T-cell exhaustion, which may limit the efficacy of ICIs in patients with CLL. We, therefore, sought to examine the efficacy of ICI in patients with these co-occurring diagnoses. PATIENTS AND

methodsIn this international multicenter study, a retrospective review of clinical databases identified patients with concomitant diagnoses of CLL and AM treated with ICI (US-MD Anderson Cancer Center, N = 24; US-Mayo Clinic, N = 15; AUS, N = 19). Objective response rates (ORRs), assessed by RECIST v1.1, and survival outcomes [overall survival (OS) and progression-free survival (PFS)] among patients with CLL and AM were assessed. Clinical factors associated with improved ORR and survival were explored. Additionally, ORR and survival outcomes were compared between the Australian CLL/AM cohort and a control cohort of 148 Australian patients with AM alone.

resultsBetween 1997 and 2020, 58 patients with concomitant CLL and AM were treated with ICI. ORRs were comparable between AUS-CLL/AM and AM control cohorts (53% versus 48%, P = 0.81). PFS and OS from ICI initiation were also comparable between cohorts. Among CLL/AM patients, a majority were untreated for their CLL (64%) at the time of ICI. Patients with prior history of chemoimmunotherapy treatment for CLL (19%) had significantly reduced ORRs, PFS, and OS.

conclusionsOur case series of patients with concomitant CLL and melanoma demonstrate frequent, durable clinical responses to ICI. However, those with prior chemoimmunotherapy treatment for CLL had significantly worse outcomes. We found that CLL disease course is largely unchanged by treatment with ICI.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellMelanomaAdultAustraliaHumansImmune Checkpoint InhibitorsProgression-Free SurvivalRetrospective StudiesImmune Checkpoint Inhibitorsanti-CTLA-4anti-PD-1chronic lymphoid leukemiaimmune checkpoint inhibitorsmelanoma

Identifiers

PMID37414216
PMCPMC11289780
OpenAlexW4383107429

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.